Ciclopirox Olamine Cream USP, 0.77%

Manufacturer
Dispensing Solutions, Inc. | PSS World Medical, Inc.
Effective date
2012-10-03
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
3
Source
full-release
Hydrated at
2026-05-31 20:16:01

Label at a glance#

ProductCiclopirox Olamine
Active ingredientCICLOPIROX OLAMINE
Label structure13 sections

Indications and uses

Ciclopirox olamine cream is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum , and Microsporum canis ; candidiasis (moniliasis) due to Candida albicans ; and tinea (pityriasis) vesicolor due to Malassezia furfur.

Dosage and administration

Gently massage ciclopirox olamine cream into the affected and surrounding skin areas twice daily, in the morning and evening. Clinical improvement with relief of pruritus and other symptoms usually occurs within the first week of treatment. If a patient shows no clinical improvement after four weeks of treatment with ciclopirox olamine cream, the diagnosis should be redetermined. Patients with tinea versicolor usu...

Storage and handling

Store at 20-25 o C (68-77 o F) [see USP Controlled Room Temperature].

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

FOR DERMATOLOGIC USE ONLY.
NOT FOR USE IN EYES.

DESCRIPTION

DESCRIPTION SECTION

Ciclopirox olamine cream USP, 0.77% is for topical use. Each gram of ciclopirox olamine cream USP contains 7.70 mg of ciclopirox (as ciclopirox olamine USP) in a water miscible vanishing cream base consisting of purified water USP, cetyl alcohol NF, light mineral oil NF, octyldodecanol NF, stearyl alcohol NF, polysorbate 60 NF, myristyl alcohol NF, sorbitan monostearate NF, lactic acid USP, and benzyl alcohol NF (1%) as preservative.

Ciclopirox olamine cream USP contains a synthetic, broad-spectrum, antifungal agent ciclopirox (as ciclopirox olamine USP). The chemical name is 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone, 2 -aminoethanol salt.

The CAS Registry Number is 41621-49-2. The chemical structure is:

Chemical Structure of Ciclopirox
Chemical Structure of Ciclopirox

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Ciclopirox is a broad-spectrum, antifungal agent that inhibits the growth of pathogenic dermatophytes, yeasts, and Malassezia furfur. Ciclopirox exhibits fungicidal activity in vitro against isolates of Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, Microsporum canis, and Candida albicans.

Pharmacokinetic studies in men with tagged ciclopirox solution in polyethylene glycol 400 showed an average of 1.3% absorption of the dose when it was applied topically to 750 cm2 on the back followed by occlusion for 6 hours. The biological half-life was 1.7 hours and excretion occurred via the kidney. Two days after application only 0.01% of the dose applied could be found in the urine. Fecal excretion was negligible.

Penetration studies in human cadaverous skin from the back, with ciclopirox olamine cream with tagged ciclopirox showed the presence of 0.8 to 1.6% of the dose in the stratum corneum 1.5 to 6 hours after application. The levels in the dermis were still 10 to 15 times above the minimum inhibitory concentration.

Autoradiographic studies with human cadaverous skin showed that ciclopirox penetrated into the hair and through the epidermis and hair follicles into the sebaceous glands and dermis, while a portion of the drug remains in the stratum corneum.

Draize Human Sensitization Assay, 21-Day Cumulative Irritancy study, Phototoxicity study, and Photo-Draize study conducted in a total of 142 healthy male subjects showed no contact sensitization of the delayed hypersensitivity type, no irritation, no phototoxicity, and no photo-contact sensitization due to ciclopirox olamine cream.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Ciclopirox olamine cream is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; candidiasis (moniliasis) due to Candida albicans; and tinea (pityriasis) vesicolor due to Malassezia furfur.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Ciclopirox olamine cream is contraindicated in individuals who have shown hypersensitivity to any of its components.

WARNINGS

WARNINGS SECTION

Ciclopirox olamine cream is not for ophthalmic use.
Keep out of the reach of children.

PRECAUTIONS

PRECAUTIONS SECTION

If a reaction suggesting sensitivity or chemical irritation should occur with the use of ciclopirox olamine cream, treatment should be discontinued and appropriate therapy instituted.

Information for Patients

INFORMATION FOR PATIENTS SECTION

The patient should be told to:

  1. Use the medication for the full treatment time even though symptoms may have improved and notify the physician if there is no improvement after four weeks.
  2. Inform the physician if the area of application shows signs of increased irritation (redness, itching, burning, blistering, swelling, or oozing) indicative of possible sensitization.
  3. Avoid the use of occlusive wrappings or dressings.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

A carcinogenicity study in female mice dosed cutaneously twice per week for 50 weeks followed by a 6-month drug-free observation period prior to necropsy revealed no evidence of tumors at the application site.

The following in vitro and in vivo genotoxicity tests have been conducted with ciclopirox olamine: studies to evaluate gene mutation in the Ames Salmonella/Mammalian Microsome Assay (negative) and Yeast Saccharomyces Cerevisiae Assay (negative) and studies to evaluate chromosome aberrations in vivo in the Mouse Dominant Lethal Assay and in the Mouse Micronucleus Assay at 500 mg/kg (negative).

The following battery of in vitro genotoxicity tests were conducted with ciclopirox: a chromosome aberration assay in V79 Chinese Hamster Cells, with and without metabolic activation (positive); a gene mutation assay in the HGPRT – test with V79 Chinese Hamster Cells (negative); and a primary DNA damage assay (i.e., unscheduled DNA Synthesis Assay in A549 Human Cells (negative). An in vitro Cell Transformation Assay in BALB/C3T3 Cells was negative for cell transformation. In an in vivo Chinese Hamster Bone Marrow Cytogenetic Assay, ciclopirox was negative for chromosome aberrations at 5,000 mg/kg.

Pregnancy Category B

PREGNANCY SECTION

Reproduction studies have been performed in the mouse, rat, rabbit, and monkey (via various routes of administration) at doses 10 times or more the topical human dose and have revealed no significant evidence of impaired fertility or harm to the fetus due to ciclopirox. There are, however, no adequate or well-controlled studies in pregnant woman. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ciclopirox olamine cream is administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients below the age of 10 years have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

In all controlled clinical studies with 514 patients using ciclopirox olamine cream and in 296 patients using the vehicle cream, the incidence of adverse reactions was low. This included pruritus at the site of application in one patient and worsening of the clinical signs and symptoms in another patient using ciclopirox olamine cream and burning in one patient and worsening of the clinical signs and symptoms in another patient using the vehicle cream.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Gently massage ciclopirox olamine cream into the affected and surrounding skin areas twice daily, in the morning and evening. Clinical improvement with relief of pruritus and other symptoms usually occurs within the first week of treatment. If a patient shows no clinical improvement after four weeks of treatment with ciclopirox olamine cream, the diagnosis should be redetermined. Patients with tinea versicolor usually exhibit clinical and mycological clearing after two weeks of treatment.

HOW SUPPLIED

HOW SUPPLIED SECTION

Ciclopirox olamine cream USP, 0.77% is supplied in 15 gram (NDC 68462-297-17), 30 gram (NDC 68462-297-35) and 90 gram (NDC 68462-297-92) tubes.

STORAGE AND HANDLING SECTION

Store at 20-25oC (68-77oF) [see USP Controlled Room Temperature].

SPL UNCLASSIFIED SECTION

Manufactured by:

Glenmark Generics Ltd.
Colvale-Bardez, Goa 403 513, India

Manufactured for:

Glenmark LogoGlenmark Logo

Glenmark Generics Inc., USA
Mahwah, NJ 07430

Questions? 1 (888)721-7115
www.glenmarkgenerics.com

February 2011

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL


NDC 68258-3996-03NDC 68258-3996-03

NDC 68258-3996-03

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
309289ciclopirox 0.77 % (ciclopirox olamine 1 % ) Topical CreamPSN3
309289ciclopirox 7.7 MG/ML Topical CreamSCD3
309289ciclopirox 0.77 % (ciclopirox olamine 1 % ) Topical CreamSY3

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
CICLOPIROX Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
f52be47f-7aa7-46c0-b1fa-50c18dd50206Product name120201029
444b3e50-f226-46ef-bfca-2e7035d140cdProduct name120190611
7cda52fc-125f-421c-8fea-bc1974370c49Product name220180703
d24c6245-86b5-4444-bc75-c1ac73ab3016Product name120180612
c7015f08-288e-4cfa-93b5-f4959a4814aeProduct name120150324
3f974526-143f-9d19-ee0c-98eeee0cdc3fProduct name120140508
597b1cfd-7b31-5048-62be-ca5cd740da2fProduct name120140508
5c035cac-559a-7171-c5cb-f0bd0d0fbc86Product name120140508
ec2149b3-5c6d-5344-f757-c86411073075Product name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
68258-3996-32019-11-27C16284748780-19855d018-de92-cd31-e053-dbdaa90ab51aCiclopirox Olamine Cream USP, 0.77%

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
68258-3996-3Ciclopirox Olamine30 g in 1 CARTONCREAM303

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
68258-3996CICLOPIROX OLAMINE CREAM [DISPENSING SOLUTIONS, INC.]3Legacy NDC, 1 package rows20121004_9982d093-9f17-48de-8d06-b8256a20c764.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
68462-297-17GM - Gram68462-29795b16de4-3cd7-4408-8d01-a05b74afb7f612012-07-24
68462-297-35GM - Gram68462-297a233910a-1751-42e0-9ab4-da513046daaa12012-07-24
68462-297-92GM - Gram68462-297da098bf8-8e98-476f-9247-3419fedd6dd712012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
CICLOPIROX OLAMINEACTIVE INGREDIENT50MD4SB4AP3
CICLOPIROXACTIVE MOIETY19W019ZDRJ3
BENZYL ALCOHOLINACTIVE INGREDIENTLKG8494WBH3
CETYL ALCOHOLINACTIVE INGREDIENT936JST6JCN3
LACTIC ACIDINACTIVE INGREDIENT33X04XA5AT3
LIGHT MINERAL OILINACTIVE INGREDIENTN6K5787QVP3
MYRISTYL ALCOHOLINACTIVE INGREDIENTV42034O9PU3
OCTYLDODECANOLINACTIVE INGREDIENT461N1O614Y3
POLYSORBATE 60INACTIVE INGREDIENTCAL22UVI4M3
SORBITAN MONOSTEARATEINACTIVE INGREDIENTNVZ4I0H58X3
STEARYL ALCOHOLINACTIVE INGREDIENT2KR89I4H1Y3
WATERINACTIVE INGREDIENT059QF0KO0R3

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 12 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
68258-399668258-3996-3
68462-297

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 11 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 9 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
LIGHT MINERAL OILLIGHT MINERAL OILN6K5787QVPCREAM / TOPICAL456 mgExact identifier — unii+route+dosage form
OCTYLDODECANOLOCTYLDODECANOL461N1O614YCREAM / TOPICAL160 mgExact identifier — unii+route+dosage form
MYRISTYL ALCOHOLMYRISTYL ALCOHOLV42034O9PUCREAM / TOPICAL3 %w/wExact identifier — unii+route+dosage form
SORBITAN MONOSTEARATESORBITAN MONOSTEARATENVZ4I0H58XCREAM / TOPICAL177 mgExact identifier — unii+route+dosage form
STEARYL ALCOHOLSTEARYL ALCOHOL2KR89I4H1YCREAM / TOPICAL162000 mgExact identifier — unii+route+dosage form
LACTIC ACIDLACTIC ACID33X04XA5ATCREAM / TOPICAL1 %w/wExact identifier — unii+route+dosage form
POLYSORBATE 60POLYSORBATE 60CAL22UVI4MCREAM / TOPICAL225 mgExact identifier — unii+route+dosage form
CETYL ALCOHOLCETYL ALCOHOL936JST6JCNCREAM / TOPICAL1280 mgExact identifier — unii+route+dosage form
BENZYL ALCOHOLBENZYL ALCOHOLLKG8494WBHCREAM / TOPICAL160 mgExact identifier — unii+route+dosage form

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A090273-001CICLOPIROXCICLOPIROX0.77%CREAM / TOPICALAB2009-11-10

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A090273-001AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-1084e616aacf4f…
2026-08-18 06:07:402026-07A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-10caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-10011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-1031067a03dcf5…
2025-08-23 18:47 UTC2025-08A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-106a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-10fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-10b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-1003ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-102680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-105bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-10d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-10d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-1079d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-10301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-101e350fbaab3a…
2024-05-31 18:47 UTC2024-05A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-108072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-105c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-105d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-104b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-1074a2ff9319b5…
2022-03-09 01:35 UTC2022-03A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-10bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-10782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-1087673890dc5c…
2021-03-12 10:30 UTC2021-03A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-105aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-108869cabd3fbd…
2020-11-12 02:37 UTC2020-11A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-10c0c555d07b60…
2019-12-14 00:12 UTC2019-12A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-103f01610625f2…
2019-09-15 20:21 UTC2019-09A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-10b00525d2431f…
2019-07-19 19:46 UTC2019-07A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-10ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-106a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-101c564ffb4f44…
2023-12-20 04:57 UTC2023-12A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-10ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-10a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-109b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-10a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-103f0d92c62455…
2023-05-13 08:27 UTC2023-05A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-10053a50430f4f…
2023-01-26 05:58 UTC2023-01A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-103bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-103a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A090273-001CICLOPIROX0.77%CREAM / TOPICALAB2009-11-10f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A090273-001AB184e616aacf4f…
2026-08-18 06:07:402026-07A090273-001AB1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A090273-001AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A090273-001AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08A090273-001AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A090273-001AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A090273-001AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A090273-001AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A090273-001AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A090273-001AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A090273-001AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A090273-001AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A090273-001AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A090273-001AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A090273-001AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A090273-001AB18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A090273-001AB15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A090273-001AB15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A090273-001AB14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A090273-001AB174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A090273-001AB1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A090273-001AB1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A090273-001AB187673890dc5c…
2021-03-12 10:30 UTC2021-03A090273-001AB15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A090273-001AB18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A090273-001AB1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A090273-001AB13f01610625f2…
2019-09-15 20:21 UTC2019-09A090273-001AB1b00525d2431f…
2019-07-19 19:46 UTC2019-07A090273-001AB1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A090273-001AB16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A090273-001AB11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A090273-001AB1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A090273-001AB1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A090273-001AB19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A090273-001AB1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A090273-001AB13f0d92c62455…
2023-05-13 08:27 UTC2023-05A090273-001AB1053a50430f4f…
2023-01-26 05:58 UTC2023-01A090273-001AB13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A090273-001AB13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A090273-001AB1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Ciclopirox OlamineCICLOPIROX OLAMINEGlenmark Pharmaceuticals Inc., USA7385cf42-9f80-4542-8e0f-a0228aa9b43a2026-01-22Warnings, Adverse reactionsExact identifier
ndc (product): 68462-297
6b02cebe-eea9-464f-88eb-7c9db13b79fc9982d093-9f17-48de-8d06-b8256a20c7642012-10-03Warnings, Adverse reactionsExact identifier
spl id: 6b02cebe-eea9-464f-88eb-7c9db13b79fc
spl set id: 9982d093-9f17-48de-8d06-b8256a20c764

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.